FORM 4

obligations may continue. See

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* NIVEN RALPH						2. Issuer Name and Ticker or Trading Symbol Aerovate Therapeutics, Inc. [AVTE]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last)	c) (First) (Middle) AEROVATE THERAPEUTICS, INC.					Date of /05/20		st Tra	nsaction	n (Mor	nth/Day/Year)		helow)		TIFIC	Other (s below)				
930 WINTER STREET, SUITE M-500						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)															X Form filed by One Reporting Person Form filed by More than One Reporting					
WALTH	ALTHAM MA 02451					Person												Tung		
(City)	(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication														
											ansaction was ditions of Rule				on or written	plan t	hat is intende	ed to		
		Tab	le I - I	Non-Deriv	vative	Sec	Securities Acquired, Disposed of, or Beneficially Owned													
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y						Execu ear) if any		eemed ution Date, :h/Day/Year)		ction Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an		(A) or 3, 4 and 5)	Benefic Owned	ies ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)		
Common Stock 04/05/202						13			M ⁽¹⁾		650	Α	\$1.74	2,259			D			
Common Stock 04/05/202					023	!3			M ⁽¹⁾		1,600	A	\$2.14	3,859			D			
Common Stock 04/05/20					023	23			S ⁽¹⁾		1,715	D	\$17.913	(2) 2	,144		D			
Common Stock 04/05/202					023	23			S ⁽¹⁾		535	D	\$19.105	6(3) 1	,609		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	eemed ution Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc		cisable and ate	7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	Ownersh Form: Direct (D or Indirect (I) (Instr.		Beneficial Ownership ct (Instr. 4)		
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares							
Stock Option (Right to Buy)	\$1.74	04/05/2023			M ⁽¹⁾			450	(4	1)	09/03/2030	Common Stock	450	\$0	20,058	3	D			
Stock Option (Right to Buy)	\$1.74	04/05/2023			M ⁽¹⁾			200	(5	5)	09/03/2030	Common Stock	200	\$0	12,688	3	D			
Stock Option (Right to Buy)	\$2.14	04/05/2023			M ⁽¹⁾			200	(6	5)	04/01/2031	Common Stock	200	\$0	14,494	1	D			
Stock Option (Right to Buy)	\$2.14	04/05/2023			M ⁽¹⁾			650	(7	7)	04/01/2031	Common Stock	650	\$0	44,058	3	D			

Explanation of Responses:

\$2.14

04/05/2023

Stock Option (Right to

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$17.63 to \$18.45, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Common Stock

750

52,982

D

04/01/2031

- 3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$18.78 to \$19.51, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 4. A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal
- 5. A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter
- 6. A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.
- 7. A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
- 8. A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.

/s/ George A. Eldridge, Attorney-in-Fact

** Signature of Reporting Person

Date

04/07/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.